Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides

被引:64
作者
Chan, C
Montaner, J
Lefebvre, EA
Morey, G
Dohn, M
McIvor, RA
Scott, J
Marina, R
Caldwell, P
机构
[1] Toronto Hosp, Toronto, ON M5G 2C4, Canada
[2] Sunnybrook Med Ctr, Toronto, ON M4N 3M5, Canada
[3] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada
[4] Clin Actuel, Montreal, PQ, Canada
[5] Glaxo Wellcome Inc, Mississauga, ON, Canada
[6] CRI S Florida, Coral Gables, FL USA
[7] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[8] Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1086/314893
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Atovaquone suspensions (750 mg and 1500 mg once a day) were compared with aerosolized pentamidine (300 mg once a month) for the prevention of Pneumocystis carinii pneumonia (PCP) in subjects with human immunodeficiency virus (HIV) infection who were intolerant to trimethoprim or sulfonamides (or both). Median time using the assigned therapy was 6.6 months, and the median follow-up was 11.3 months. Intent-to-treat analyses (n = 549) showed no statistically significant differences among subjects with regard to the incidence of PCP (26%, 22%, and 17%, respectively) or mortality (20%, 13%, and 18%, respectively). The incidence of treatment-limiting adverse events with atovaquone was significantly higher (P < .01). There was, however, no significant difference in the time using therapy, Incidences of PCP and death were higher in subjects receiving 750 mg of atovaquone than in subjects receiving 1500 mg. Atovaquone suspension at 1500 mg once a day has an efficacy similar to that of aerosolized pentamidine for prevention of PCP in HIV-infected subjects and is a safe, effective alternative in those who are intolerant to trimethoprim or sulfonamides.
引用
收藏
页码:369 / 376
页数:8
相关论文
共 22 条
[1]   TRIMETREXATE FOR THE TREATMENT OF PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
ALLEGRA, CJ ;
CHABNER, BA ;
TUAZON, CU ;
OGATAARAKAKI, D ;
BAIRD, B ;
DRAKE, JC ;
SIMMONS, JT ;
LACK, EE ;
SHELHAMER, JH ;
BALIS, F ;
WALKER, R ;
KOVACS, JA ;
LANE, HC ;
MASUR, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (16) :978-985
[2]   A RANDOMIZED TRIAL OF 3 ANTIPNEUMOCYSTIS AGENTS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
BOZZETTE, SA ;
FINKELSTEIN, DM ;
SPECTOR, SA ;
FRAME, P ;
POWDERLY, WG ;
HE, WL ;
PHILLIPS, L ;
CRAVEN, D ;
VANDERHORST, C ;
FEINBERG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (11) :693-699
[3]  
*CDCP, 1995, CLIN INFECT DIS S1, V21, P232
[4]  
Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P17
[5]   DEVELOPMENTAL THERAPEUTICS AND THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
DEVITA, VT ;
BRODER, S ;
FAUCI, AS ;
KOVACS, JA ;
CHABNER, BA .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (04) :568-581
[6]   Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both [J].
El-Sadr, WM ;
Murphy, RL ;
Yurik, RM ;
Luskin-Hawk, R ;
Cheung, TW ;
Balfour, HH ;
Eng, R ;
Hooton, TM ;
Kerkering, TM ;
Schutz, M ;
van der Horst, C ;
Hafner, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (26) :1889-1895
[7]  
ELSADR W, 1997, 35 M INF DIS SOC AM
[8]  
FLEMING TR, 1990, J ACQ IMMUN DEF SYND, V3, pS82
[9]  
Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204
[10]   A CONTROLLED TRIAL OF TRIMETHOPRIM SULFAMETHOXAZOLE OR AEROSOLIZED PENTAMIDINE FOR SECONDARY PROPHYLAXIS OF PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME - AIDS CLINICAL-TRIALS GROUP PROTOCOL-021 [J].
HARDY, WD ;
FEINBERG, J ;
FINKELSTEIN, DM ;
POWER, ME ;
HE, W ;
KACZKA, C ;
FRAME, PT ;
HOLMES, M ;
WASKIN, H ;
FASS, RJ ;
POWDERLY, WG ;
STEIGBIGEL, RT ;
ZUGER, A ;
HOLZMAN, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (26) :1842-1848